Angela Vincent

List of Publications by Year
in descending order

602	51,433	744 114	1481 207
papers	citations	h-index	g-index

756	756	756	23564
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis. Neurology: Neuroimmunology and NeuroInflammation, 2024, 11, .	7.1	1
2	Posthospitalization COVID-19 cognitive deficits at 1â€‰year are global and associated with elevated brain injury markers and gray matter volume reduction. Nature Medicine, 2024, 31, 245-257.	25.6	3
3	Myasthenia research over the last 50 years â€“ a personal perspective. RRNMF Neuromuscular Journal, 2023, 4, .	0.1	0
4	Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses. Nature Communications, 2023, 14, .	14.1	16
5	Neuroimmune disorders in COVID-19. Journal of Neurology, 2022, 269, 2827-2839.	3.4	38
6	Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective. Frontiers in Immunology, 2022, 13, .	5.0	10
7	Slow Channel Syndrome Revisited: 40 Years Clinical Follow-Up and Genetic Characterization of Two Cases. Journal of Neuromuscular Diseases, 2022, 9, 525-532.	2.8	1
8	Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 995-1000.	2.0	27
9	Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice. Neuropathology and Applied Neurobiology, 2021, 47, 316-327.	3.4	11
10	Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. Biological Psychiatry, 2021, 90, 9-15.	1.7	16
11	Autoantibodies in Japanese patients with ocular myasthenia gravis. Muscle and Nerve, 2021, 63, 262-267.	2.6	11
12	Neuronal surface antibodies are common in children with narcolepsy and active movement disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 111-112.	2.0	2
13	Comparison of N-methyl-d-aspartate receptor antibody assays using live or fixed substrates. Journal of Neurology, 2021, 268, 1818-1826.	3.4	9
14	Multimodal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy. Annals of Neurology, 2021, 89, 753-768.	6.6	22
15	Systemic and cerebrospinal fluid immune and complement activation in Ugandan children and adolescents with longâ€standing nodding syndrome: A caseâ€control study. Epilepsia Open, 2021, 6, 297-309.	2.9	13
16	Using AChR antibody titres to predict treatment responses in myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 915-915.	2.0	5
17	Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	7.1	7
18	Antibodies to neuronal surface antigens in patients with a clinical diagnosis of neurodegenerative disorder. Brain, Behavior, and Immunity, 2021, 96, 106-112.	4.3	19

#	Article	IF	Citations
19	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, .	2.5	14
20	Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis. Communications Biology, 2021, 4, .	4.5	23
21	The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, .	1.0	4
22	Myasthenia Gravis and Related Disorders. , 2020, , 1011-1033.		1
23	Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry,the, 2020, 7, 93-108.	9.0	264
24	Paediatric myasthenia gravis: Prognostic factors for drug free remission. Neuromuscular Disorders, 2020, 30, 120-127.	0.7	23
25	SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	7.1	12
26	The Structure, Function, and Physiology of the Fetal and Adult Acetylcholine Receptor in Muscle. Frontiers in Molecular Neuroscience, 2020, 13, .	3.5	53
27	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2020, 26, 2590-2604.	8.3	17
28	Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment. Frontiers in Molecular Neuroscience, 2020, 13, .	3.5	29
29	Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30649-30660.	7.7	42
30	The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis. Frontiers in Molecular Neuroscience, 2020, 13, .	3.5	119
31	Autoantibodies to the N-Methyl-D-Aspartate Receptor in Adolescents With Early Onset Psychosis and Healthy Controls. Frontiers in Psychiatry, 2020, 11, .	2.7	6
32	Neuronal antibody prevalence in children with seizures under 3 years. Neurology, 2020, 95, .	1.3	12
33	Maternal-Autoantibody-Related (MAR) Autism: Identifying Neuronal Antigens and Approaching Prospects for Intervention. Journal of Clinical Medicine, 2020, 9, 2564.	2.6	11
34	Maternal Immunity in Autism Spectrum Disorders: Questions of Causality, Validity, and Specificity. Journal of Clinical Medicine, 2020, 9, 2590.	2.6	11
35	Disentangling etiologies of CNS infections in Singapore using multiple correspondence analysis and random forest. Scientific Reports, 2020, 10, .	3.7	6
36	Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 526-532.	2.0	16

#	Article	IF	Citations
37	Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophrenia Research, 2020, 222, 455-461.	2.4	22
38	ANTIBODIES AND RECEPTORS: From Neuromuscular Junction to Central Nervous System. Neuroscience, 2020, 439, 48-61.	2.5	21
39	In vivo Mechanisms of Antibody-Mediated Neurological Disorders: Animal Models and Potential Implications. Frontiers in Neurology, 2020, 10, .	2.5	17
40	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, .	2.5	33
41	The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain, 2020, 143, 3104-3120.	8.9	859
42	Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology, 2020, 95, .	1.3	18
43	Autoimmune psychosis â€“ Authors' reply. Lancet Psychiatry,the, 2020, 7, 123-125.	9.0	4
44	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	3.4	21
45	Case report: Headache and neurological deficits with CSF lymphocytosis (HaNDL) associated with P/Q type voltage-gated calcium channel antibodies (CACNA1A). Cephalalgia, 2020, 40, 1003-1007.	4.4	7
46	Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain, 2019, 142, 2303-2318.	8.9	292
47	Autoimmune Encephalitis. , 2019, , 21-43.		0
48	Glycine receptor autoantibodies disrupt inhibitory neurotransmission. Brain, 2019, 142, 3398-3410.	8.9	61
49	AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Frontiers in Neurology, 2019, 10, .	2.5	65
50	O10.3. EXPOSURE TO COMMON INFECTIOUS PATHOGENS IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS: CLINICAL AND IMMUNOBIOLOGICAL ASSOCIATIONS. Schizophrenia Bulletin, 2019, 45, S190-S191.	4.3	0
51	Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. Brain, Behavior, and Immunity, 2019, 81, 665-669.	4.3	18
52	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	19.1	164
53	Rapsyn facilitates recovery from desensitization in fetal and adult acetylcholine receptors expressed in a muscle cell line. Journal of Physiology, 2019, 597, 3713-3725.	3.2	14
54	Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1021-1026.	2.0	39

#	Article	IF	Citations
55	Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodies. Brain, 2019, 142, 2000-2012.	8.9	38
56	Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clinical Therapeutics, 2019, 41, 836-847.	2.9	10
57	False-positive acetylcholine receptor antibody results in patients without myasthenia gravis. Journal of Neuroimmunology, 2019, 332, 69-72.	2.4	18
58	In vitro neuronal network activity as a new functional diagnostic system to detect effects of Cerebrospinal fluid from autoimmune encephalitis patients. Scientific Reports, 2019, 9, .	3.7	7
59	Acquired neuromyotonia in children with <scp>CASPR</scp>2 and <scp>LGI</scp>1 antibodies. Developmental Medicine and Child Neurology, 2019, 61, 1344-1347.	3.9	19
60	GP230â€…Fetal acetylcholine receptor inactivation due to maternal myasthenia gravis: an underrecognised, devastating but potentially preventable and treatable disorder. , 2019, , A124.1-A124.		0
61	Muscle acetylcholine receptor conversion into chloride conductance at positive potentials by a single mutation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21228-21235.	7.7	4
62	Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight, 2019, 4, .	5.5	42
63	Immune or Genetic-Mediated Disruption of CASPR2 Causes Pain Hypersensitivity Due to Enhanced Primary Afferent Excitability. Neuron, 2018, 97, 806-822.e10.	12.8	124
64	Autoimmune neurological disorders-does the age matter?. European Journal of Paediatric Neurology, 2018, 22, 341-343.	2.1	3
65	Serological and experimental studies in different forms of myasthenia gravis. Annals of the New York Academy of Sciences, 2018, 1413, 143-153.	4.5	47
66	The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain, 2018, 141, 348-356.	8.9	300
67	Autoantibody Testing in theÂDiagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases. , 2018, , 153-168.		2
68	Acquired Neuromyotonia. , 2018, , 239-250.		0
69	Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain, 2018, 141, 13-36.	8.9	162
70	Brain-relevant antibodies in first-episode psychosis: a matched caseâ€“control study. Psychological Medicine, 2018, 48, 1257-1263.	4.6	20
71	Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody. Multiple Sclerosis Journal, 2018, 24, 679-684.	4.1	11
72	Antibody-mediated central nervous system diseases. Brain and Neuroscience Advances, 2018, 2, 239821281881749.	1.8	11

#	Article	IF	Citations
73	NMDA-receptor antibodies alter cortical microcircuit dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, .	7.7	39
74	Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia. JAMA Neurology, 2018, 75, 1519.	14.3	46
75	Investigation of neuronal auto-antibodies in children diagnosed with epileptic encephalopathy of unknown cause. Brain and Development, 2018, 40, 909-917.	1.3	14
76	Glutamate receptor Î´2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology, 2018, 91, .	1.3	43
77	Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes. Seminars in Neurology, 2018, 38, 344-354.	2.0	30
78	Antiglycine receptor antibody related disease: a case series and literature review. European Journal of Neurology, 2018, 25, 1290-1298.	3.7	56
79	Do we need to measure specific antibodies in patients with limbic encephalitis?. Neurology, 2017, 88, 508-509.	1.3	10
80	Pediatric Autoimmune Epileptic Encephalopathies. Journal of Child Neurology, 2017, 32, 418-428.	1.8	12
81	First reported cases of anti-NMDA receptor encephalitis in Vietnamese adolescents and adults. Journal of the Neurological Sciences, 2017, 373, 250-253.	1.4	17
82	Recurrent Optic Neuritis Associated With MOG Antibody Seropositivity. Neurologist, 2017, 22, 101-102.	1.1	12
83	IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, .	7.1	57
84	Redefining progressive encephalomyelitis with rigidity and myoclonus after the discovery of antibodies to glycine receptors. Current Opinion in Neurology, 2017, 30, 310-316.	4.1	39
85	Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy. Sleep, 2017, 40, .	0.8	33
86	CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 718-721.	2.0	38
87	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	2.0	103
88	Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain, 2017, 140, 617-627.	8.9	222
89	Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology, 2017, 89, 269-278.	1.3	161
90	Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain, 2017, 140, 1212-1219.	8.9	90

#	Article	IF	Citations
91	Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry,the, 2017, 4, 42-48.	9.0	146
92	Paraneoplastic cerebellar degeneration and lambertâ€eaton myasthenia in a patient with merkel cell carcinoma and voltageâ€gated calcium channel antibodies. Muscle and Nerve, 2017, 56, 998-1000.	2.6	11
93	IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. Journal of Autoimmunity, 2017, 77, 104-115.	6.8	99
94	High sensitivity and specificity in proposed clinical diagnostic criteria for antiâ€Nâ€methylâ€<scp>D</scp>â€aspartate receptor encephalitis. Developmental Medicine and Child Neurology, 2017, 59, 1256-1260.	3.9	45
95	Detection of NMDARs Antibodies in Encephalitis. Methods in Molecular Biology, 2017, , 117-126.	0.0	4
96	Persistent microglial activation and synaptic loss with behavioral abnormalities in mouse offspring exposed to CASPR2-antibodies in utero. Acta Neuropathologica, 2017, 134, 567-583.	7.9	48
97	Pathogenic potential of antibodies to the <scp>GABA_B</scp> receptor. Epilepsia Open, 2017, 2, 355-359.	2.9	33
98	1633â€...Linear- versus conformational-protein directed autoantibodies in neuropsychiatric systemic lupus erythematosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A10.1-A10.	2.0	0
99	Cell- and Single Molecule-Based Methods to Detect Anti- N -Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project. Biological Psychiatry, 2017, 82, 766-772.	1.7	67
100	Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children. European Journal of Paediatric Neurology, 2017, 21, 414-417.	2.1	15
101	Pitfalls in the detection of N -methyl- d -aspartate-receptor (NMDA-R) antibodies. Clinical Biochemistry, 2017, 50, 354-355.	1.8	15
102	Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain, 2017, 140, 3128-3138.	8.9	567
103	Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease. Acta Neuropathologica Communications, 2017, 5, .	5.1	39
104	Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Research, 2016, 5, 1513.	0.6	143
105	Progress in autoimmune epileptic encephalitis. Current Opinion in Neurology, 2016, 29, 151-157.	4.1	19
106	Characteristics Of acetylcholineâ€receptorâ€antibodyâ€“negative myasthenia gravis in a South African cohort. Muscle and Nerve, 2016, 54, 1023-1029.	2.6	33
107	Autoantibodies and pain. Current Opinion in Supportive and Palliative Care, 2016, 10, 137-142.	1.8	11
108	Anti-N-Methyl-D-Aspartate Receptor Encephalitis In A Young Child With Histological Evidence On Brain Biopsy Of Coexistent Herpes Simplex Virus Type 1 Infection. Pediatric Infectious Disease Journal, 2016, 35, 347-349.	1.3	15

#	Article	IF	Citations
109	Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies. Developmental Medicine and Child Neurology, 2016, 58, 836-841.	3.9	29
110	Nâ€methylâ€<scp>d</scp>â€aspartate (<scp>NMDA</scp>) receptor antibodies encephalitis mimicking an autistic regression. Developmental Medicine and Child Neurology, 2016, 58, 1092-1094.	3.9	32
111	ImmunoglobuliNin theTreatment ofEncephalitis (IgNiTE): protocol for a multicentre randomised controlled trial. BMJ Open, 2016, 6, e012356.	2.0	19
112	Stiff person syndrome in South Asia. BMC Research Notes, 2016, 9, .	1.6	4
113	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	2.0	221
114	The Importance of Keeping in Mind the Diagnosis of N -Methyl-D-Aspartate Receptor Encephalitis. Biological Psychiatry, 2016, 80, e15.	1.7	1
115	Autoimmunity in neuropsychiatric disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, , 269-282.	0.0	12
116	Autoimmune movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, , 301-315.	0.0	16
117	Introduction to autoimmune neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, , 3-14.	0.0	16
118	Voltage-gated potassium channelâ€“complex autoimmunity and associated clinical syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, , 185-197.	0.0	45
119	Neuromuscular junction disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, , 447-466.	0.0	51
120	Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 511-522.	25.5	708
121	Compromised fidelity of Bâ€cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Annals of Clinical and Translational Neurology, 2016, 3, 443-454.	3.8	42
122	Neuronal antibodies in pediatric epilepsy: Clinical features and longâ€term outcomes of a historical cohort not treated with immunotherapy. Epilepsia, 2016, 57, 823-831.	4.8	33
123	Postencephalitic epilepsy and drugâ€resistant epilepsy after infectious and antibodyâ€associated encephalitis in childhood: Clinical and etiologic risk factors. Epilepsia, 2016, 57, .	4.8	56
124	Neuroimaging in encephalitis: analysis of imaging findings and interobserver agreement. Clinical Radiology, 2016, 71, 1050-1058.	1.1	48
125	Autoimmune synaptopathies. Nature Reviews Neuroscience, 2016, 17, 103-117.	10.0	79
126	Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome. Neurology, 2016, 86, 692-694.	1.3	10

#	Article	IF	Citations
127	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 676-677.	2.0	7
128	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	19.1	2,944
129	Antibodies to AMPA receptors in Rasmussen's encephalitis. European Journal of Paediatric Neurology, 2016, 20, 222-227.	2.1	19
130	Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings. Journal of Neurology, 2016, 263, 455-466.	3.4	41
131	Pregnancy outcomes in aquaporin-4â€“positive neuromyelitis optica spectrum disorder. Neurology, 2016, 86, 79-87.	1.3	97
132	N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness. Biological Psychiatry, 2016, 79, e61.	1.7	6
133	Autoantibody-associated autoimmune-encephalitis in Sri Lankan patients. Journal of the Neurological Sciences, 2015, 357, e195.	1.4	0
134	Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study. PLoS ONE, 2015, 10, e0143558.	2.5	29
135	Fetal acetylcholine receptor inactivation syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, .	7.1	57
136	Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Experimental Neurology, 2015, 270, 66-71.	4.1	53
137	Antibodies to GABA ‹sub›A‹/sub› receptor Î±1 and Î²2 subunits. Neurology, 2015, 84, 1233-1241.	1.3	163
138	Epileptogenic effects of NMDAR antibodies in a passive transfer mouse model. Brain, 2015, 138, 3159-3167.	8.9	92
139	Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, .	7.1	14
140	Central nervous system antibody-mediated diseases with autonomic involvement â€“ Focus on VGKC-complex (LGI1, CASPR2), NMDAR and GlyR antibodies. Autonomic Neuroscience: Basic and Clinical, 2015, 192, 15.	3.3	1
141	Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 692-694.	2.0	44
142	Collagen Q â€“ A potential target for autoantibodies in myasthenia gravis. Journal of the Neurological Sciences, 2015, 348, 241-244.	1.4	46
143	Clinical relevance of serum antibodies to extracellular‹i›N‹/i›-methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	2.0	95
144	Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 470-472.	2.0	95

#	Article	IF	Citations
145	Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis modelâ€"Recommendations for methods and experimental designs. Experimental Neurology, 2015, 270, 3-10.	4.1	27
146	Prevalence Rate of N-methyl-d-aspartate (NMDA) Receptor Antibodies in First Episode Psychosis.. European Psychiatry, 2015, 30, 1568.	0.3	4
147	OP87 â€“ 3001: Paediatric neurological syndromes associated with glycine receptor antibodies. European Journal of Paediatric Neurology, 2015, 19, S27.	2.1	0
148	Paraneoplastic neurologic disorders in small cell lung carcinoma. Neurology, 2015, 85, 235-239.	1.3	108
149	Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. Experimental Neurology, 2015, 270, 29-40.	4.1	27
150	Targeting the Interleukin 6 Receptor to Treat Neuromyelitis Optica. JAMA Neurology, 2015, 72, 747.	14.3	4
151	Autoimmune Encephalopathies. Pediatric Clinics of North America, 2015, 62, 667-685.	1.5	23
152	Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurology, 2015, 72, 642.	14.3	127
153	Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, .	7.1	192
154	Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome. Pediatrics, 2015, 135, e974-e984.	4.1	117
155	MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, .	7.1	335
156	Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibodyâ€"Consuming Effect?. Journal of Neuropathology and Experimental Neurology, 2015, 74, 194-197.	1.9	6
157	N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children. Archives of Disease in Childhood, 2015, 100, 521-526.	1.6	109
158	Neuromyelitis optica in a child with Aicardi-GoutiÃ^res syndrome. Neurology, 2015, 85, 381-383.	1.3	21
159	Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, .	7.1	200
160	GLYCINE RECEPTOR ANTIBODYâ€"A MARKER FOR NMO/ NON-MS DEMYELINATION?. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.36-e4.	2.0	0
161	A PROSPECTIVE CLINICAL AND IMMUNOLOGICAL STUDY OF LATE ONSET MYASTHENIA GRAVIS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.49-e4.	2.0	0
162	Neuroinflammation: Ways in Which the Immune System Affects the Brain. Neurotherapeutics, 2015, 12, 896-909.	6.5	188

#	Article	IF	Citations
163	Clinical relevance of voltage-gated potassium channelâ€“complex antibodies in children. Neurology, 2015, 85, 967-975.	1.3	56
164	Pediatric Herpes Simplex Virus Encephalitis Complicated by N-Methyl-D-aspartate Receptor Antibody Encephalitis. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e17-e21.	1.5	22
165	Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. Neurotherapeutics, 2015, 13, 147-162.	6.5	71
166	Myasthenia gravis: a clinical-immunological update. Journal of Neurology, 2015, 263, 826-834.	3.4	134
167	Isolated new onset â€˜atypicalâ€™ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. Journal of Neurology, 2015, 263, 370-379.	3.4	37
168	Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination. PLoS ONE, 2015, 10, e0129555.	2.5	20
169	Low Levels of Vitamin D in Neuromyelitis Optica Spectrum Disorder: Association with Disease Disability. PLoS ONE, 2014, 9, e107274.	2.5	33
170	Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 456-461.	2.0	68
171	NMDA receptor antibodies associated with distinct white matter syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, .	7.1	86
172	Voltage-Gated Potassium Channels Autoantibodies in a Child with Rasmussen Encephalitis. Neuropediatrics, 2014, 45, 336-340.	1.2	9
173	RETROGRADE AMNESIA FOLLOWING AUTOIMMUNE LIMBIC ENCEPHALITIS. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.79-e4.	2.0	0
174	VGKC-complex antibody encephalitis. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 657-659.	0.5	4
175	Gerstmann-StraÃ¼ssler-Scheinker disease. Neurology, 2014, 82, 2107-2111.	1.3	23
176	Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop. Pain Medicine, 2014, 15, 1072-1082.	2.2	22
177	Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series. Schizophrenia Research, 2014, 160, 193-195.	2.4	58
178	EEGâ€confirmed epileptic activity in a cat with VGKCâ€complex/LGI1 antibodyâ€associated limbic encephalitis. Epileptic Disorders, 2014, 16, 116-120.	1.9	18
179	Advances in the clinical science of the motor unit. Current Opinion in Neurology, 2014, 27, 503-505.	4.1	0
180	PREGNANCY OUTCOME IN AQUAPORIN-4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER: A MULTI-CENTER RETROSPECTIVE COHORT STUDY. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.74-e4.	2.0	0

#	Article	IF	Citations
181	IgG and Complement Deposition and Neuronal Loss in Cats and Humans With Epilepsy and Voltage-Gated Potassium Channel Complex Antibodies. Journal of Neuropathology and Experimental Neurology, 2014, 73, 403-413.	1.9	40
182	AUTOANTIBODIES IN ALZHEIMER DISEASE;. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e3-e3.	2.0	0
183	Features of Neuromyelitis Optica Spectrum Disorders and Aquaporin-4 With Myelin-Oligodendrocyte Glycoprotein Antibodiesâ€"Reply. JAMA Neurology, 2014, 71, 924.	14.3	15
184	How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Archives of Disease in Childhood, 2014, 99, 539-542.	1.6	95
185	The role of muscleâ€specific tyrosine kinase (<scp>MuSK</scp>) and mystery of <scp>MuSK</scp> myasthenia gravis. Journal of Anatomy, 2014, 224, 29-35.	1.8	41
186	Characterisation of a syndrome of autoimmune adult onset focal epilepsy and encephalitis. Journal of Clinical Neuroscience, 2014, 21, 1169-1175.	1.7	16
187	Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. Journal of Neuroimmunology, 2014, 271, 66-68.	2.4	28
188	Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia, 2014, 55, 414-422.	4.8	61
189	Paraneoplastic cerebellar syndrome and sensory ganglionopathy with papillary thyroid carcinoma. Journal of the Neurological Sciences, 2014, 341, 183-184.	1.4	11
190	Myasthenia Gravis and Related Disorders. , 2014, , 777-791.		0
191	Hypoventilation in glycine-receptor antibody related progressive encephalomyelitis, rigidity and myoclonus. Journal of Clinical Neuroscience, 2014, 21, 876-878.	1.7	14
192	Nâ€methylâ€Dâ€aspartate receptor antibodyâ€associated movement disorder without encephalopathy. Developmental Medicine and Child Neurology, 2014, 56, 190-193.	3.9	32
193	Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurology, The, 2014, 13, 195-205.	19.1	374
194	Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies. JAMA Neurology, 2014, 71, 276.	14.3	519
195	Do Neuronal Autoantibodies Cause Psychosis? A Neuroimmunological Perspective. Biological Psychiatry, 2014, 75, 269-275.	1.7	52
196	Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha-1a adrenoceptors. Pain, 2014, 155, 2408-2417.	4.6	72
197	Cell-surface neuronal antibodies in patients with Japanese encephalitis virus. Journal of Neuroimmunology, 2014, 275, 6-7.	2.4	1
198	Glycine receptor antibody mediated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM): a rare but treatable neurological syndrome. Practical Neurology, 2014, 14, 123-127.	1.4	31

#	Article	IF	Citations
199	Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191.	2.4	55
200	Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain, 2014, 137, 2178-2192.	8.9	456
201	Nâ€methylâ€Dâ€aspartate receptor antibodies in postâ€herpes simplex virus encephalitis neurological relapse. Movement Disorders, 2014, 29, 90-96.	5.3	196
202	Autoantibodies at the neuromuscular junctionÂâ€Âlink to the central nervous system. Revue Neurologique, 2014, 170, 584-586.	0.6	1
203	Cellâ€surface central nervous system autoantibodies: Clinical relevance and emerging paradigms. Annals of Neurology, 2014, 76, 168-184.	6.6	154
204	Glycine receptor antibodies in a boy with focal epilepsy and episodic behavioral disorder. Journal of the Neurological Sciences, 2014, 343, 180-182.	1.4	30
205	Anti-NMDAR encephalitis misdiagnosed asÂHashimoto's encephalopathy. European Journal of Paediatric Neurology, 2014, 18, 72-74.	2.1	18
206	Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 625-630.	2.0	102
207	Limbic Encephalitis Associated With Elevated Antithyroid Antibodies. Journal of Child Neurology, 2014, 29, 769-773.	1.8	12
208	Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population. Journal of the Neurological Sciences, 2014, 343, 82-87.	1.4	31
209	Epilepsy-related psychosis: A role for autoimmunity?. Epilepsy and Behavior, 2014, 36, 33-38.	2.0	22
210	Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 2014, 261, 337-342.	4.1	14
211	Glycine receptor antibodies in 2 cases of new, adult-onset epilepsy. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, .	7.1	13
212	Guillainâ€BarrÃ© syndrome associated with <scp>CASPR2</scp> antibodies: two paediatric cases. Journal of the Peripheral Nervous System, 2014, 19, 246-249.	3.8	16
213	Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions. Journal of Neurology, 2014, 262, 1081-1095.	3.4	31
214	An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre. Journal of Neurology, 2014, 262, 418-424.	3.4	34
215	Autoimmune Encephalitisâ€”Antibody Targets and Their Potential Pathogenicity in Immunotherapy-responsive Syndromes. European Neurological Review, 2014, 9, 87.	0.1	1
216	GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nature Genetics, 2013, 45, 1061-1066.	16.3	362

#	Article	IF	Citations
217	Long-term clinical course with voltage-gated potassium channel antibody in Morvanâ€™s syndrome. Journal of Neurology, 2013, 260, 2407-2408.	3.4	8
218	Autoantibodies in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurology, 2013, 70, 919.	14.3	34
219	Autoimmune myasthenia gravis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, , 1465-1468.	0.0	18
220	CACNA1H antibodies associated with headache with neurological deficits and cerebrospinal fluid lymphocytosis (HaNDL). Cephalalgia, 2013, 33, 123-129.	4.4	37
221	Prevalence, clinical features and treatment outcomes of patients with myasthenia gravis positive for antibodies to muscle-specific kinase in Thailand. Journal of Clinical Neuroscience, 2013, 20, 707-709.	1.7	4
222	Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. Journal of the Neurological Sciences, 2013, 335, 221-223.	1.4	34
223	Developments in autoimmune channelopathies. Autoimmunity Reviews, 2013, 12, 678-681.	7.1	26
224	Organic neuropsychiatry: a treatable cause of suicidal behaviour. Practical Neurology, 2013, 13, 44-48.	1.4	1
225	Symptomatic brain involvement as the initial manifestation of neuromyelitis optica. Journal of Clinical Neuroscience, 2013, 20, 938-942.	1.7	9
226	Acute disseminated encephalomyelitis associated with positive voltage gated potassium channel complex antibody. Multiple Sclerosis and Related Disorders, 2013, 2, 147-150.	2.1	2
227	Neuromyelitis Optica IgG Causes Placental Inflammation and Fetal Death. Journal of Immunology, 2013, 191, 2999-3005.	0.6	89
228	N-Methyl-d-aspartate receptor (NMDAR) antibodies in post herpes simplex virus encephalitis (HSVE) neurological relapse. Journal of the Neurological Sciences, 2013, 333, e128.	1.4	1
229	Survivin Blockade Sensitizes Rhabdomyosarcoma Cells for Lysis by Fetal Acetylcholine Receptorâ€“Redirected T Cells. American Journal of Pathology, 2013, 182, 2121-2131.	3.6	16
230	Ion channels in genetic and acquired forms of epilepsy. Journal of Physiology, 2013, 591, 753-764.	3.2	127
231	Autoimmune epilepsy in children: Case series and proposed guidelines for identification. Epilepsia, 2013, 54, 1036-1045.	4.8	79
232	A pilot study on neurological manifestations and antibodies against antigens in children with hematological and other cancers. European Journal of Paediatric Neurology, 2013, 17, 97-101.	2.1	4
233	Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain, 2013, 136, 3151-3162.	8.9	363
234	Progressive Encephalomyelitis With Rigidity and Myoclonus. JAMA Neurology, 2013, 70, 498.	14.3	52

#	Article	IF	Citations
235	Narcolepsy and H1N1 vaccination. Current Opinion in Pulmonary Medicine, 2013, 19, 587-593.	2.8	20
236	Neuronal Surface and Glutamic Acid Decarboxylase Autoantibodies in Nonparaneoplastic Stiff Person Syndrome. JAMA Neurology, 2013, 70, 1140.	14.3	58
237	Creutzfeld-Jakob Diseaseâ€"Reply. JAMA Neurology, 2013, 70, 1589.	14.3	1
238	Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 Antibodies. JAMA Neurology, 2013, 70, 1375.	14.3	100
239	Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 748-755.	2.0	220
240	Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia, 2013, 54, 1028-1035.	4.8	195
241	Immune-mediated pediatric epilepsies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, , 521-531.	0.0	10
242	Guillain-BarrÃ©-like syndrome associated with lung adenocarcinoma and CASPR2 antibodies. Muscle and Nerve, 2013, 48, 836-837.	2.6	14
243	Autoantibodies to neuronal antigens in children with newâ€onset seizures classified according to the revised <scp>ILAE</scp> organization of seizures and epilepsies. Epilepsia, 2013, 54, 2091-2100.	4.8	52
244	MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. PLoS ONE, 2013, 8, e80695.	2.5	152
245	Acute Measles Encephalitis in Partially Vaccinated Adults. PLoS ONE, 2013, 8, e71671.	2.5	16
246	Immunization against GAD Induces Antibody Binding to GAD-Independent Antigens and Brainstem GABAergic Neuronal Loss. PLoS ONE, 2013, 8, e72921.	2.5	27
247	Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 437-440.	2.0	102
248	138â€...Differences in outcomes in neuromyelitis optica between a Japanese cohort and a predominantly Caucasian cohort from the UK. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.91-e1.	2.0	0
249	162â€...The association of two rare neurological diseases: a multicentre study of 16 patients with AChR antibody myasthenia gravis and AQP4 antibody neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.118-e1.	2.0	0
250	Antiâ€"Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia. Archives of Neurology, 2012, 69, .	6.8	18
251	0842â€...Myelin-oligodendrocyte glycoprotein antibody as a cause of acute disseminated encephalomyelitis with a neuromyelitis optica-like phenotype in adults. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.152-e1.	2.0	0
252	Republished review: Autoantibody testing in encephalopathies. Postgraduate Medical Journal, 2012, 88, 280-289.	1.9	1

#	Article	IF	Citations
253	Febrile Infection-Related Epilepsy Syndrome without Detectable Autoantibodies and Response to Immunotherapy: A Case Series and Discussion of Epileptogenesis in FIRES. Neuropediatrics, 2012, 43, 209-216.	1.2	72
254	Antibody-mediated encephalitis: a treatable cause of schizophrenia. British Journal of Psychiatry, 2012, 200, 92-94.	2.3	92
255	Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis. Archives of Neurology, 2012, 69, .	6.8	121
256	Paediatric autoimmune encephalitis: evaluation of clinical features, laboratory investigations and outcome. Archives of Disease in Childhood, 2012, 97, A135.1-A135.	1.6	0
257	094â€…Anti-NMDA receptor antibodies disrupt cortical network activity in vitro. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.42-e1.	2.0	0
258	Authors' reply. British Journal of Psychiatry, 2012, 201, 74-74.	2.3	0
259	The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arquivos De Neuro-Psiquiatria, 2012, 70, 300-304.	1.3	17
260	New serological markers for the differential diagnosis of autoimmune limbic	0.3	3
261	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain, 2012, 135, 1834-1849.	8.9	357
262	More movements in neuroimmunology. Brain, 2012, 135, 3201-3202.	8.9	3
263	Supranuclear gaze palsy in glycine receptor antibodyâ€positive progressive encephalomyelitis with rigidity and myoclonus. Movement Disorders, 2012, 27, 1833-1834.	5.3	22
264	Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. Journal of Neurology, 2012, 259, 1566-1573.	3.4	49
265	NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. Journal of Neurology, 2012, 259, 1979-1981.	3.4	44
266	End of the bed (end of the video) diagnosis: Figure 1. Practical Neurology, 2012, 12, 135-138.	1.4	1
267	Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 638-645.	2.0	250
268	Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain, 2012, 135, 1622-1638.	8.9	574
269	Autoantibody testing in encephalopathies. Practical Neurology, 2012, 12, 4-13.	1.4	10
270	Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: A case report. Neuromuscular Disorders, 2012, 22, 546-548.	0.7	20

#	Article	IF	Citations
271	Serologic diagnosis of NMO. Neurology, 2012, 78, 665-671.	1.3	452
272	VGKCâ€complex antibody mediated encephalitis presenting with psychiatric features and neuroleptic malignant syndrome â€“ further expanding the phenotype. Developmental Medicine and Child Neurology, 2012, 54, 575-576.	3.9	13
273	A clinicoâ€radiological phenotype of voltageâ€gated potassium channel complex antibodyâ€mediated disorder presenting with seizures and basal ganglia changes. Developmental Medicine and Child Neurology, 2012, 54, 1157-1159.	3.9	8
274	Antibodies identified by cellâ€based assays in myasthenia gravis and associated diseases. Annals of the New York Academy of Sciences, 2012, 1274, 92-98.	4.5	39
275	The search for new antigenic targets in myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 123-128.	4.5	76
276	Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex. Journal of the Neurological Sciences, 2012, 312, 52-56.	1.4	23
277	Myasthenia gravis and neuromyelitis optica spectrum disorder. Neurology, 2012, 78, 1601-1607.	1.3	181
278	Neutrophil protease inhibition reduces neuromyelitis opticaâ€“immunoglobulin Gâ€“induced damage in mouse brain. Annals of Neurology, 2012, 71, 323-333.	6.6	153
279	Morvan syndrome: Clinical and serological observations in 29 cases. Annals of Neurology, 2012, 72, 241-255.	6.6	492
280	Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. Experimental Neurology, 2012, 234, 506-512.	4.1	110
281	Anti-N-Methyl-d-aspartate-receptor encephalitis: Cognitive profile in two children. European Journal of Paediatric Neurology, 2012, 16, 79-82.	2.1	19
282	Febrile infection-related epilepsy syndrome is not caused by SCN1A mutations. Epilepsy Research, 2012, 100, 194-198.	1.9	11
283	Management of suspected viral encephalitis in children â€“ Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group National Guidelines. Journal of Infection, 2012, 64, 449-477.	2.9	151
284	Limbic encephalitis in children and adolescents. Archives of Disease in Childhood, 2011, 96, 186-191.	1.6	135
285	Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS. Journal of Clinical Oncology, 2011, 29, 902-908.	17.1	215
286	Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. Journal of the Neurological Sciences, 2011, 301, 71-76.	1.4	37
287	Limbic encephalitis presenting as a post-partum psychiatric condition. Journal of the Neurological Sciences, 2011, 308, 152-154.	1.4	8
288	Paroxysmal EEG pattern in a child with N-methyl-d-aspartate receptor antibody encephalitis. Developmental Medicine and Child Neurology, 2011, 53, 764-767.	3.9	20

#	Article	IF	Citations
289	Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Developmental Medicine and Child Neurology, 2011, 53, 1053-1057.	3.9	111
290	Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies. Developmental Medicine and Child Neurology, 2011, 53, 1058-1060.	3.9	40
291	Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia, 2011, 52, 121-131.	4.8	90
292	Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia, 2011, 52, 12-17.	4.8	64
293	Potentially pathogenic autoantibodies associated with epilepsy and encephalitis in children and adults. Epilepsia, 2011, 52, 8-11.	4.8	33
294	T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. Journal of Neuroimmunology, 2011, 235, 27-32.	2.4	32
295	Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-BehÃ§et's disease. Journal of Neuroimmunology, 2011, 239, 91-97.	2.4	22
296	Autoimmunity against the Î²2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain, 2011, 152, 2690-2700.	4.6	162
297	Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurology, The, 2011, 10, 759-772.	19.1	524
298	Surviving stiff-person syndrome: a case report. Journal of Neurology, 2011, 258, 1898-1900.	3.4	3
299	Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. Journal of Neurology, 2011, 258, 2176-2180.	3.4	26
300	NMDA Receptor Antibody Encephalitis. Current Neurology and Neuroscience Reports, 2011, 11, 298-304.	4.7	93
301	Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Annals of Neurology, 2011, 69, 892-900.	6.6	749
302	Antiglycine-receptor encephalomyelitis with rigidity. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1399-1401.	2.0	125
303	Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis/New serological markers for the differential diagnosis of autoimmune limbic encephalitis. Laboratoriums Medizin, 2011, 35, 329-342.	0.3	4
304	John Newsom-Davis: clinician-scientist and so much more. Brain, 2011, 134, 3755-3774.	8.9	6
305	VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology, 2011, 76, 1252-1255.	1.3	94
306	Progressive encephalomyelitis with rigidity and myoclonus: Resolution after thymectomy. Neurology, 2011, 76, 303-304.	1.3	54

#	Article	IF	Citations
307	Progressive encephalomyelitis with rigidity and myoclonus. Neurology, 2011, 77, 439-443.	1.3	97
308	Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis. Neurology India, 2011, 59, 47.	0.4	48
309	Autoimmune mediated neuromuscular junction defects. Current Opinion in Neurology, 2010, 23, 489-495.	4.1	70
310	Anti-N-methyl-D-aspartate receptor antibodies: A potentially treatable cause of encephalitis in the intensive care unit. Critical Care Medicine, 2010, 38, 679-682.	0.6	87
311	The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Current Opinion in Neurology, 2010, 23, 144-150.	4.1	99
312	N-methyl-D-aspartate limbic encephalitis: Diagnosis should respect well-recognized criteria. Critical Care Medicine, 2010, 38, 1615-1616.	0.6	1
313	Prospective Study into the Incidence of Lambert Eaton Myasthenic Syndrome in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 34-38.	1.1	48
314	Caspr2 Antibodies in Patients with Thymomas. Journal of Thoracic Oncology, 2010, 5, S277-S280.	1.1	59
315	Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. Journal of Neurology, 2010, 257, 920-925.	3.4	19
316	Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems. Journal of Clinical Immunology, 2010, 30, 97-102.	3.4	34
317	Anti-N-methyl-D-Aspartate-Receptor Encephalitis in a Four-Year-Old Girl. Journal of Pediatrics, 2010, 156, 332-334.	2.1	19
318	Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Annals of Neurology, 2010, 67, 470-478.	6.6	436
319	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia, 2010, 51, 1898-1901.	4.8	42
320	PAW33 Aquaporin-4 M 23 isoform provides a more sensitive assay for aquaporin-4 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e32-e32.	2.0	4
321	Successful treatment of antiN-methyl-d-aspartate receptor limbic encephalitis in a 22-monthold child with plasmapheresis and pharmacological immunomodulation. Archives of Disease in Childhood, 2010, 95, 312-312.	1.6	35
322	The Association of Bullous Pemphigoid With Cerebrovascular Disease and Dementia. Archives of Dermatology, 2010, 146, .	2.2	107
323	Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain, 2010, 133, 349-361.	8.9	463
324	Successful 'passive transfer' of paraneoplastic stiff person syndrome with antibodies to an intracellular antigen. Brain, 2010, 133, 3164-3165.	8.9	11

#	Article	IF	Citations
325	PATU1 Characteristic faciobrachial dystonic seizures as an immunotherapy-responsive prodrome to voltage-gated potassium channel antibody-associated limbic encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e24-e24.	2.0	0
326	Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain, 2010, 133, 2727-2733.	8.9	30
327	Interferon Beta Treatment in Neuromyelitis Optica. Archives of Neurology, 2010, 67, .	6.8	282
328	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences, 2010, 298, 158-162.	1.4	151
329	N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain, 2010, 133, 1655-1667.	8.9	883
330	Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvanâ€™s syndrome and acquired neuromyotonia. Brain, 2010, 133, 2734-2748.	8.9	1,150
331	Anti-NMDA Receptor Encephalitis With Atypical Brain Changes on MRI. Pediatric Neurology, 2010, 43, 274-278.	1.9	15
332	Non-paraneoplastic limbic encephalitis characterized by mesio-temporal seizures and extratemporal lesions: A case report. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 446-449.	2.3	16
333	Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infectious Diseases, The, 2010, 10, 835-844.	15.7	1,097
334	Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. Journal of Neurology, 2010, 258, 464-470.	3.4	63
335	Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology, 2010, 258, 686-688.	3.4	271
336	Immunocapture and Identification of Cell Membrane Protein Antigenic Targets of Serum Autoantibodies. Molecular and Cellular Proteomics, 2009, 8, 1688-1696.	4.8	8
337	ENDPLATE DESTRUCTION DUE TO MATERNAL ANTIBODIES IN ARTHROGRYPOSIS MULTIPLEX CONGENITA. Neurology, 2009, 73, 1806-1808.	1.3	14
338	Successful treatment of anti-N-methyl-D-aspartate receptor encephalitis presenting with catatonia. Archives of Disease in Childhood, 2009, 94, 314-316.	1.6	66
339	Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women With New-Onset Epilepsy. Archives of Neurology, 2009, 66, .	6.8	151
340	Nâ€methylâ€‹scp›D‹/scp›â€aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Annals of Neurology, 2009, 66, 704-709.	6.6	213
341	Autoimmune disorders of the neuromuscular junction. Current Opinion in Pharmacology, 2009, 9, 336-340.	4.1	49
342	Immune-mediated rippling muscle disease with myasthenia gravis: A report of seven patients with long-term follow-up in two. Neuromuscular Disorders, 2009, 19, 223-228.	0.7	39

#	Article	IF	Citations
343	MuSK-antibody-positive myasthenia gravis in a South Asian population. Journal of the Neurological Sciences, 2009, 284, 33-35.	1.4	16
344	The Effect of Plasma From Muscle-Specific Tyrosine Kinase Myasthenia Patients on Regenerating Endplates. American Journal of Pathology, 2009, 175, 1536-1544.	3.6	35
345	Antiâ€NMDA receptor encephalitis: a video case report. Epileptic Disorders, 2009, 11, 267-269.	1.9	9
346	Autoimmune channelopathies: new antibody-mediated disorders of the central nervous system. F1000 Biology Reports, 2009, 1, .	2.5	11
347	Epitopes expressed in myasthenia gravis (MG) thymomas are not recognized by patients' T cells or autoantibodies. Clinical and Experimental Immunology, 2008, 112, 17-20.	3.5	4
348	Relative frequency of VGKC and â€˜classicalâ€™ paraneoplastic antibodies in patients with limbic encephalitis. Journal of Neurology, 2008, 255, 1100-1101.	3.4	23
349	New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin. Journal of Neurology, 2008, 255, 1603-1604.	3.4	8
350	Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies. Annals of the New York Academy of Sciences, 2008, 1132, 84-92.	4.5	90
351	Autoimmunizing Mechanisms in Thymoma and Thymus*. Annals of the New York Academy of Sciences, 2008, 1132, 163-173.	4.5	85
352	Congenital Myasthenic Syndromes and the Formation of the Neuromuscular Junction. Annals of the New York Academy of Sciences, 2008, 1132, 99-103.	4.5	28
353	Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. Journal of Neuroimmunology, 2008, 195, 151-156.	2.4	124
354	Autoimmune channelopathies: John Newsom-Davis's work and legacy. Journal of Neuroimmunology, 2008, 201-202, 245-249.	2.4	10
355	CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. Journal of the Neurological Sciences, 2008, 268, 74-77.	1.4	73
356	Autoantibodies in different forms of myasthenia gravis and in the Lambertâ€“Eaton syndrome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, , 213-227.	0.0	2
357	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. Nature Clinical Practice Neurology, 2008, 4, 202-214.	1.5	286
358	Stiff, twitchy or wobblyâ€”are GAD antibodies pathogenic?. Brain, 2008, 131, 2536-2537.	8.9	31
359	Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis. Archives of Neurology, 2008, 65, .	6.8	254
360	FETAL ACETYLCHOLINE RECEPTOR INACTIVATION SYNDROME AND MATERNAL MYASTHENIA GRAVIS. Neurology, 2008, 71, 2010-2012.	1.3	44

#	Article	IF	Citations
361	PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY. Neurology, 2008, 71, 1291-1292.	1.3	330
362	IgG1 antibodies to acetylcholine receptors in â€˜seronegativeâ€™ myasthenia gravisâ€. Brain, 2008, 131, 1940-1952.	8.9	416
363	Autoimmune disorders of the neuromuscular junction. Neurology India, 2008, 56, 305.	0.4	23
364	Autoantibodies in neuromuscular transmission disorders. Annals of Indian Academy of Neurology, 2008, 11, 140.	0.7	3
365	John Newsom-Davis, 1932â€“2007. Nature Clinical Practice Neurology, 2007, 3, 647-647.	1.5	0
366	Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scandinavian Journal of Gastroenterology, 2007, 42, 1289-1293.	1.8	44
367	Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies. Clinical Neurophysiology, 2007, 118, 269-277.	1.0	36
368	Overexpression of Rapsyn in Rat Muscle Increases Acetylcholine Receptor Levels in Chronic Experimental Autoimmune Myasthenia Gravis. American Journal of Pathology, 2007, 170, 644-657.	3.6	33
369	Myasthenia Gravis Thymus. American Journal of Pathology, 2007, 171, 893-905.	3.6	110
370	Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nature Medicine, 2007, 13, 1483-1489.	25.6	349
371	An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature, 2007, 448, 934-937.	40.1	161
372	Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. Journal of Neuroimmunology, 2007, 185, 136-144.	2.4	35
373	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. PLoS Medicine, 2007, 4, e133.	8.1	182
374	MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain, 2006, 129, 1481-1492.	8.9	160
375	MuSK antibody-positive, seronegative myasthenia gravis in Korea. Journal of Clinical Neuroscience, 2006, 13, 353-355.	1.7	33
376	Autoimmune Channelopathies and Related Neurological Disorders. Neuron, 2006, 52, 123-138.	12.8	96
377	Fetal arthrogryposis and maternal serum antibodies. Neuromuscular Disorders, 2006, 16, 481-491.	0.7	31
378	Use of Antiâ€Nerve Antibodies. , 2006, , 87-93.		0

#	Article	IF	Citations
379	Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Research, 2006, 71, 135-141.	1.9	124
380	A 45-year history of acquired autoimmune neuromyotonia. Journal of Neurology, 2006, 253, 1243-1245.	3.4	1
381	Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: The role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Movement Disorders, 2006, 21, 1737-1741.	5.3	55
382	Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle and Nerve, 2006, 33, 568-570.	2.6	55
383	Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Annals of Neurology, 2006, 59, 178-181.	6.6	203
384	Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain, 2006, 129, 1570-1584.	8.9	139
385	Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations. Brain, 2006, 129, 2773-2783.	8.9	52
386	Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology, 2006, 66, 1772-1774.	1.3	112
387	Dok-7 Mutations Underlie a Neuromuscular Junction Synaptopathy. Science, 2006, 313, 1975-1978.	38.2	235
388	Rhabdomyosarcoma Lysis by T Cells Expressing a Human Autoantibody-Based Chimeric Receptor Targeting the Fetal Acetylcholine Receptor. Cancer Research, 2006, 66, 24-28.	0.6	35
389	Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Current Opinion in Neurology, 2005, 18, 519-525.	4.1	126
390	Myasthenia gravis with MuSK antibodies. Practical Neurology, 2005, 5, 356-359.	1.4	6
391	Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. British Journal of Pharmacology, 2005, 146, 1027-1039.	6.5	120
392	Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation. Journal of Neuroimmunology, 2005, 162, 149-156.	2.4	24
393	Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome. Journal of Neuroimmunology, 2005, 162, 184-189.	2.4	42
394	Anti-glial nuclear antibody: Marker of lung cancer-related paraneoplastic neurological syndromes. Journal of Neuroimmunology, 2005, 165, 166-171.	2.4	117
395	MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. Journal of Neuroimmunology, 2005, 170, 41-48.	2.4	56
396	Acetylcholine receptors loss and postsynaptic damage in MuSK antibodyâ€“positive myasthenia gravis. Annals of Neurology, 2005, 57, 289-293.	6.6	158

#	Article	IF	Citations
397	Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Annals of Neurology, 2005, 57, 444-448.	6.6	209
398	Antibodies associated with paraneoplastic neurological disorders. Neurological Sciences, 2005, 26, s3-s4.	1.7	6
399	Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 714-718.	2.0	58
400	Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain, 2005, 128, 2327-2337.	8.9	64
401	Autoimmune channelopathies. Nature Clinical Practice Neurology, 2005, 1, 22-33.	1.5	62
402	Mechanisms in myasthenia gravis. Drug Discovery Today Disease Mechanisms, 2005, 2, 401-408.	1.4	2
403	Seronegative Myasthenia Gravis. Seminars in Neurology, 2004, 24, 125-133.	2.0	78
404	A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition. Human Molecular Genetics, 2004, 13, 2947-2957.	3.1	28
405	Encephalitis lethargica: part of a spectrum of post-streptococcal autoimmune diseases?. Brain, 2004, 127, 2-3.	8.9	33
406	Low-voltage-activated A-current controls the firing dynamics of mouse hypothalamic orexin neurons. European Journal of Neuroscience, 2004, 20, 3281-3285.	3.7	27
407	Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Annals of Neurology, 2004, 55, 580-584.	6.6	386
408	Lack of association between acetylcholine receptor ? polymorphisms and early-onset myasthenia gravis. Muscle and Nerve, 2004, 29, 436-439.	2.6	7
409	Potassium channel antibodyâ€associated encephalopathy: a potentially immunotherapyâ€responsive form of limbic encephalitis. Brain, 2004, 127, 701-712.	8.9	1,005
410	Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders, 2004, 14, 356-364.	0.7	59
411	Myasthenia Gravis. Autoimmunity, 2004, 37, 317-319.	3.1	19
412	Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain, 2004, 127, 269-279.	8.9	50
413	Chapter 16 Antibody-mediated disorders of neuromuscular transmission. Supplements To Clinical Neurophysiology, 2004, , 147-158.	0.0	5
414	Structural Abnormalities of the AChR Caused by Mutations Underlying Congenital Myasthenic Syndromes. Annals of the New York Academy of Sciences, 2003, 998, 114-124.	4.5	6

#	Article	IF	Citations
415	Pathogenic Autoantibodies in the Lambert-Eaton Myasthenic Syndrome. Annals of the New York Academy of Sciences, 2003, 998, 187-195.	4.5	39
416	LEMS IgG Binds to Extracellular Determinants on N-Type Voltage-Gated Calcium Channels, but Does Not Reduce VGCC Expression. Annals of the New York Academy of Sciences, 2003, 998, 196-199.	4.5	6
417	Autoimmune Disorders of Neuronal Potassium Channels. Annals of the New York Academy of Sciences, 2003, 998, 202-210.	4.5	101
418	Antibodies in Myasthenia Gravis and Related Disorders. Annals of the New York Academy of Sciences, 2003, 998, 324-335.	4.5	98
419	Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurology, The, 2003, 2, 99-106.	19.1	204
420	Maternal neuronal antibodies associated with autism and a language disorder. Annals of Neurology, 2003, 53, 533-537.	6.6	178
421	Antibodies to Neuronal Targets in Neurological and Psychiatric Diseases. Annals of the New York Academy of Sciences, 2003, 992, 48-55.	4.5	16
422	Amnesia, cerebral atrophy, and autoimmunity. Lancet, The, 2003, 361, 1266.	35.3	39
423	Autoantibodies to ion channels at the neuromuscular junction. Autoimmunity Reviews, 2003, 2, 94-100.	7.1	49
424	Evidence of underdiagnosis of myasthenia gravis in older people. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1105-1108.	2.0	174
425	Spontaneous production of anti-IFN-Â and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. International Immunology, 2003, 15, 903-913.	3.4	65
426	Antibodies against Muscle-Specific Kinase in Juvenile Myasthenia Gravis. Neuropediatrics, 2003, 34, 110-111.	1.2	4
427	New autoantibody mediated disorders of the central nervous system. Current Opinion in Neurology, 2003, 16, 351-357.	4.1	37
428	AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology, 2002, 59, 1682-1688.	1.3	66
429	Mutations in congenital myasthenic syndromes reveal an varepsilon subunit C-terminal cysteine, C470, crucial for maturation and surface expression of adult AChR. Human Molecular Genetics, 2002, 11, 3087-3096.	3.1	41
430	Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain, 2002, 125, 1887-1895.	8.9	407
431	A Role for Autoantibodies in Some Cases of Acquired Non-Paraneoplastic Gut Dysmotility. Scandinavian Journal of Gastroenterology, 2002, 37, 166-170.	1.8	39
432	Diseases of the neuromuscular junction. Current Opinion in Pharmacology, 2002, 2, 296-301.	4.1	32

#	Article	IF	Citations
433	Expression of foetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disorders. Brain, 2002, 125, 1309-1319.	8.9	42
434	Reflections on the VIth International Congress of Neuroimmunology held at the Edinburgh International Conference Centre, Edinburgh, September 3â€“7, 2001. Journal of Neuroimmunology, 2002, 124, 1-3.	2.4	2
435	Maternal antibody-mediated dyslexia? Evidence for a pathogenic serum factor in a mother of two dyslexic children shown by transfer to mice using behavioural studies and magnetic resonance spectroscopy. Journal of Neuroimmunology, 2002, 130, 243-247.	2.4	24
436	Measuring and evaluating the significance of autoantibodies in neurological disorders. Clinical and Applied Immunology Reviews, 2002, 3, 127-151.	0.6	9
437	Antibodies to Acetylcholine Receptor in Parous Women with Myasthenia: Evidence for Immunization by Fetal Antigen. Laboratory Investigation, 2002, 82, 1407-1417.	3.5	40
438	Unravelling the pathogenesis of myasthenia gravis. Nature Reviews Immunology, 2002, 2, 797-804.	17.9	356
439	Myasthenia gravis: diagnostic and management dilemmas. Current Opinion in Neurology, 2001, 14, 583-589.	4.1	31
440	Stiff-Person Syndrome: Autoimmunity and the Central Nervous System. CNS Spectrums, 2001, 6, 427-433.	0.7	19
441	Potassium channel antibodies in two patients with reversible limbic encephalitis. Annals of Neurology, 2001, 50, 73-78.	6.6	367
442	Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine, 2001, 7, 365-368.	25.6	1,040
443	Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. Journal of Neuroimmunology, 2001, 113, 153-162.	2.4	56
444	Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration. Journal of Neuroimmunology, 2001, 114, 259-264.	2.4	26
445	Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. Journal of Neuroimmunology, 2001, 115, 127-134.	2.4	36
446	Cerebellar Ataxia With Antiâ€“Glutamic Acid Decarboxylase Antibodies. Archives of Neurology, 2001, 58, 225.	6.8	362
447	End-plate gamma- and varepsilon-subunit mRNA levels in AChR deficiency syndrome due to varepsilon-subunit null mutations. Brain, 2001, 124, 1362-1372.	8.9	48
448	Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain, 2001, 124, 2417-2426.	8.9	338
449	Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology, 2001, 57, 1579-1582.	1.3	96
450	Acetylcholine receptor Î´ subunit mutations underlie a fast-channel myasthenic syndrome and arthrogryposis multiplex congenita. Journal of Clinical Investigation, 2001, 108, 125-130.	9.1	36

#	Article	IF	Citations
451	Asymptomatic maternal myasthenia as a cause of the Pena-Shokeir phenotype. , 2000, 92, 1-6.		58
452	The spectrum of mutations causing end-plate acetylcholinesterase deficiency. Annals of Neurology, 2000, 47, 162-170.	6.6	114
453	Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. FEBS Journal, 2000, 267, 6717-6728.	0.3	69
454	Neuroprotective autoimmunityâ€"a double-edged sword?. Nature Medicine, 2000, 6, 383-385.	25.6	1
455	Persistent facial myokymia: an autoimmune aetiology?. Journal of Neurology, 2000, 247, 554-555.	3.4	9
456	Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia. Archives of Neurology, 2000, 57, 527.	6.8	81
457	Autoantibody screening in subacute cerebellar ataxia. Lancet, The, 2000, 356, 565-566.	35.3	33
458	Neuromyotonia in association with essential thrombocythemia. Journal of the Neurological Sciences, 2000, 173, 78-79.	1.4	6
459	Neuromyotonia in association with systemic sclerosis. Journal of Neurology, 1999, 246, 976-977.	3.4	11
460	Monoclonal antibodies raised against human acetylcholine receptor bind to all five subunits of the fetal isoform. Journal of Neuroimmunology, 1999, 98, 112-120.	2.4	28
461	Pathogenic autoantibodies to neuronal proteins in neurological disorders. Journal of Neuroimmunology, 1999, 100, 169-180.	2.4	44
462	Physicochemical and immunological studies of the N-terminal domain Ã¯Â¿Â½of theTorpedoacetylcholine receptor Î±-subunit expressed in Ã¯Â¿Â½Escherichia coli. FEBS Journal, 1999, 259, 310-319.	0.3	33
463	Immune-mediated peripheral neuropathies and voltage-gated sodiums channels. , 1999, 22, 108-110.		20
464	A Comparison of MyoD1 and Fetal Acetylcholine Receptor Expression in Childhood Tumors and Normal Tissues. Journal of Molecular Diagnostics, 1999, 1, 23-31.	2.9	27
465	[36] Antibodies to ion channels. Methods in Enzymology, 1999, , 677-704.	1.0	0
466	Antibodies to Ion Channels in Paraneoplastic Disorders. Brain Pathology, 1999, 9, 285-291.	4.7	21
467	Immunology of the neuromuscular junction and presynaptic nerve terminal. Current Opinion in Neurology, 1999, 12, 545-551.	4.1	11
468	Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. Journal of Clinical Investigation, 1999, 103, 1031-1038.	9.1	69

#	Article	IF	Citations
469	Neuronal Staining Patterns in Sera from Patients with Lambert-Eaton Myasthenic Syndromea. Annals of the New York Academy of Sciences, 1998, 841, 684-686.	4.5	1
470	Evidence for an Association between Human Acetylcholine Receptor and Rapsyna. Annals of the New York Academy of Sciences, 1998, 841, 14-16.	4.5	4
471	A Single Nucleotide Deletion in the e Subunit of the Acetylcholine Receptor (AChR) in Five Congenital Myasthenic Syndrome Patients with AChR Deficiencya. Annals of the New York Academy of Sciences, 1998, 841, 195-198.	4.5	12
472	Expression of Muscle Proteins in Thymomas of Patients with Myasthenia Gravisa. Annals of the New York Academy of Sciences, 1998, 841, 411-413.	4.5	5
473	Antibodies Affecting Ion Channel Function in Acquired Neuromyotonia, in Seropositive and Seronegative Myasthenia Gravis, and in Antibody-mediated Arthrogryposis Multiplex Congenita. Annals of the New York Academy of Sciences, 1998, 841, 482-496.	4.5	41
474	Seronegative Myasthenia Plasmas and Non-IgG Fractions Transiently Inhibit nAChR Functiona. Annals of the New York Academy of Sciences, 1998, 841, 501-504.	4.5	8
475	An Animal Model of Maternal Antibodymediated Arthrogryposis Multiplex Congenita (AMC)a. Annals of the New York Academy of Sciences, 1998, 841, 565-567.	4.5	7
476	The Role of Autoantibodies in Lambert-Eaton Myasthenic Syndromeaa. Annals of the New York Academy of Sciences, 1998, 841, 596-605.	4.5	33
477	Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunological Reviews, 1998, 164, 157-168.	6.8	93
478	IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody- mediated disease. European Journal of Immunology, 1998, 28, 2487-2497.	3.5	98
479	Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFNÎ³ secretion and cytotoxicity. Journal of Neuroimmunology, 1998, 86, 53-62.	2.4	30
480	Î± -Bungarotoxin binding to human muscle acetylcholine receptor: measurement of affinity, delineation of AChR subunit residues crucial to binding, and protection of AChR function by synthetic peptides. Neurochemistry International, 1998, 32, 427-433.	3.6	14
481	A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.. Journal of Clinical Investigation, 1998, 101, 2268-2277.	9.1	72
482	Antibodies to 125I-glutamic acid decarboxylase in patients with stiff man syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 395-397.	2.0	26
483	Postsynaptic Abnormalities at the Neuromuscular Junctions of Utrophin-deficient Mice. Journal of Cell Biology, 1997, 136, 883-894.	4.8	205
484	Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library. International Immunology, 1997, 9, 1311-1318.	3.4	45
485	Mutations in Different Functional Domains of the Human Muscle Acetylcholine Receptor Â Subunit in Patients with the Slow-Channel congenital Myasthenic Syndrome. Human Molecular Genetics, 1997, 6, 767-774.	3.1	124
486	Mechanisms of Action of Antiâ€GM₁and Antiâ€GQ_{1b}Ganglioside Antibodies in Guillainâ€BarrÃ© Syndrome. Journal of Infectious Diseases, 1997, 176, S144-S149.	4.0	38

#	Article	IF	Citations
487	Congenital myasthenic syndromes. Current Opinion in Neurology, 1997, 10, 402-407.	4.1	13
488	Disorders of the Human Neuromuscular Junction. Advances in Organ Biology, 1997, , 315-349.	0.0	4
489	Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Journal of the Neurological Sciences, 1997, 147, 35-42.	1.4	228
490	Identification of phospholipase A2 and neurotoxic activities in the venom of the New Guinean small-eyed snake (Micropechis ikaheka). Toxicon, 1997, 35, 101-109.	1.8	9
491	Spontaneous neutralising antibodies to interferon-a and interleukin-12 in thymoma-associated autoimmune disease. Lancet, The, 1997, 350, 1596-1597.	35.3	94
492	Lack of effect of Miller Fisher sera/plasmas on transmitter release from PC12 cells. Journal of Neuroimmunology, 1997, 80, 1-5.	2.4	7
493	Genes at the junctionâ€"candidates for congenital myasthenic syndromes. Trends in Neurosciences, 1997, 20, 15-22.	13.4	55
494	Antibodies specific for fetal AChR induce arthrogryposis multiplex congenita in developing mice: an animal model for transfer of pathogenic antibodies. Journal of Reproductive Immunology, 1997, 34, 95-96.	1.1	0
495	Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Annals of Neurology, 1997, 41, 238-246.	6.6	301
496	Stable functional expression of the adult subtype of human muscle acetylcholine receptor following transfection of the human rhabdomyosarcoma cell line TE671 with cDNA encoding the Îµ subunit. Neuroscience Letters, 1996, 207, 57-60.	1.9	51
497	Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis. Journal of Neuroimmunology, 1996, 64, 179-183.	2.4	29
498	Cloning of cDNA Encoding Human Rapsyn and Mapping of the RAPSN Gene Locus to Chromosome 11p11.2â€"p11.1. Genomics, 1996, 35, 613-616.	2.7	17
499	Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1996, 71, 173-177.	2.4	102
500	A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18.. Journal of Clinical Investigation, 1996, 97, 1155-1164.	9.1	84
501	CLONING AND EXPRESSION OF HUMAN S-LAMININ. Biochemical Society Transactions, 1996, 24, 278S-278S.	4.2	0
502	Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Current Opinion in Immunology, 1996, 8, 865-871.	5.6	33
503	A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology, 1996, 47, 1552-1555.	1.3	71
504	Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function.. Journal of Clinical Investigation, 1996, 98, 2358-2363.	9.1	140

#	Article	IF	Citations
505	Acquired neuromyotonia: Evidence for autoantibodies directed against K⁺channels of peripheral nerves. Annals of Neurology, 1995, 38, 714-722.	6.6	388
506	Differences in processing of an autoantigen by DR4:Dw4.2 and DR4:Dw14.2 antigen-presenting cells. European Journal of Immunology, 1995, 25, 2119-2122.	3.5	7
507	Autoantibodies, neurotoxins and the nervous system. Journal of Physiology (Paris), 1995, 89, 129-136.	1.8	15
508	An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 85-87.	2.0	217
509	Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells. Journal of Neuroimmunology, 1995, 56, 65-76.	2.4	50
510	IVth Congress of the International Society of Neuroimmunology Amsterdam, the Netherlands, 23â€“27 October 1994. Journal of Neuroimmunology, 1995, 58, 117-120.	2.4	1
511	Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet, The, 1995, 346, 24-25.	35.3	143
512	Immunogenicity of Human Recombinant Acetylcholine Receptor Î± Subunit: Cytoplasmic Epitopes Dominate the Antibody Response in four Mouse Strains. Autoimmunity, 1994, 18, 113-119.	3.1	7
513	Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line. Pflugers Archiv European Journal of Physiology, 1994, 428, 492-498.	2.4	27
514	Passive transfer of seronegative myasthenia gravis to mice. Muscle and Nerve, 1994, 17, 1393-1400.	2.6	163
515	Response to human acetylcholine receptor Î±138â€“199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunology Letters, 1994, 39, 269-275.	2.4	34
516	Letter to the editor. Journal of Neuroimmunology, 1994, 53, 115.	2.4	1
517	Molecular characterisation of the human muscle nicotinic acetylcholine receptor genes. Neuromuscular Disorders, 1994, 4, S50.	0.7	0
518	Aetiological factors in development of myasthenia gravis. Advances in Neuroimmunology, 1994, 4, 355-371.	1.7	36
519	Is the AChR Î±373â€“380 sequence a T or B cell epitope in thymoma associated-myasthenia gravis?. Neuromuscular Disorders, 1994, 4, S34.	0.7	1
520	Fetal acetylcholine receptor function reduced by serum from asymptomatic mother with history of fetal arthrogryposis. Neuromuscular Disorders, 1994, 4, S19.	0.7	0
521	Single channel properties of human muscle nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes. Neuromuscular Disorders, 1994, 4, S47.	0.7	0
522	Autoantibodies to voltage-gated potassium channels in acquired neuromyotonia. Neuromuscular Disorders, 1994, 4, S28.	0.7	4

#	Article	IF	Citations
523	â€œSpreadingâ€•of B cell determinants in experimental myasthenia gravis induced by acetylcholine receptor peptides. Neuromuscular Disorders, 1994, 4, S45.	0.7	0
524	Lambert-Eaton myasthenic syndrome IgG identifies calcium channel subtypes in neuronal cell lines. Neuromuscular Disorders, 1994, 4, S11.	0.7	0
525	Thymoma epithelial cells can present AChR antigens to specific T cells. Neuromuscular Disorders, 1994, 4, S31.	0.7	0
526	Involvement of cation channels in autoimmune disease. Biochemical Society Transactions, 1994, 22, 488-491.	4.2	1
527	Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes.. Journal of Clinical Investigation, 1994, 93, 1361-1369.	9.1	69
528	Pathogenic autoimmunity to affinity-purified mouse acetylcholine receptor induced without adjuvant in BALB/c mice. European Journal of Immunology, 1993, 23, 973-976.	3.5	42
529	Primary structure of the human muscle acetylcholine receptor. cDNA cloning of the gamma and e subunits. FEBS Journal, 1993, 215, 229-238.	0.3	67
530	Congenital Myasthenic Syndromes. Neuromuscular Disorders, 1993, 3, 183-190.	0.7	27
531	Presentation of endogenous acetylcholine receptor epitope by an MHC class II-transfected human muscle cell line to a specific CD4+ T cell clone from a myasthenia gravis patient. Journal of Neuroimmunology, 1993, 46, 57-65.	2.4	27
532	Human nicotinic acetylcholine receptor Î±-subunit isoforms: origins and expression. Nucleic Acids Research, 1993, 21, 5463-5467.	16.2	23
533	Role of acetylcholine receptor antibody complexes in muscle in experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1992, 36, 117-125.	2.4	16
534	Stimulation of human T cells by sparse antigens captured on immunomagnetic particles. Journal of Immunological Methods, 1992, 155, 41-48.	1.5	20
535	Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet, The, 1991, 338, 75-77.	35.3	216
536	Antibody-mediated neurological disease. Current Opinion in Neurobiology, 1991, 1, 430-435.	5.0	4
537	Role of acetylcholine receptor antibody complexes in experimental autoimmune myasthenia gravis. Journal of Autoimmunity, 1991, 4, xxviii.	6.8	0
538	Fine specificity of an AChR-reactive T cell line from a young myasthenic patient. Journal of Autoimmunity, 1991, 4, xi.	6.8	0
539	Acquired neuromyotonia (Isaac's syndrome): Evidence for an antibody-mediated mechanism. Journal of Neuroimmunology, 1991, 35, 68.	2.4	0
540	Binding of acetylcholine receptor Î±-subunit peptides to HLA-A2. Journal of Neuroimmunology, 1991, 35, 115.	2.4	0

#	Article	IF	Citations
541	Selecting T cell lines in myasthenia gravis (MG) using recombinant human autoantigen. Journal of Neuroimmunology, 1991, 35, 116.	2.4	0
542	Lectins affect ACHR function in TE671 cells: A possible model for seronegative MG plasma. Journal of Neuroimmunology, 1991, 35, 194.	2.4	0
543	Autoimmunity to acetylcholine receptors in myasthenia gravis. Biochemical Society Transactions, 1991, 19, 180-183.	4.2	10
544	Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7343-7347.	7.7	87
545	BOOK REVIWES. Brain, 1990, 113, 1920-1921.	8.9	0
546	Î±-Neurotoxin binding to the human nicotinic acetylcholine receptor. Biochemical Society Transactions, 1990, 18, 889-890.	4.2	2
547	A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle and Nerve, 1990, 13, 407-413.	2.6	43
548	Plasma from anti-AChR Ab negative MG patients reduces Na+ influx into TE671 cells. Journal of Autoimmunity, 1989, 2, 930.	6.8	0
549	Motor Nerve Terminal Calcium Channels in Lambert-Eaton Myasthenic Syndrome.. Annals of the New York Academy of Sciences, 1989, 560, 278-290.	4.5	20
550	Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends in Neurosciences, 1989, 12, 496-502.	13.4	166
551	Human muscle acetylcholine receptor: cloning and expression in Escherichia coli of cDNA for the Î±-subunit. Biochemical Society Transactions, 1989, 17, 219-220.	4.2	24
552	Epitopes on human acetylcholine receptor Î±-subunit: binding of monoclonal antibodies to recombinant and synthetic peptides. Biochemical Society Transactions, 1989, 17, 220-221.	4.2	15
553	Lambert-Eaton syndrome antibodies: reaction with membranes from a small cell lung cancer xenograft. Journal of Neuroimmunology, 1988, 18, 97-104.	2.4	15
554	Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect. Journal of the Neurological Sciences, 1988, 84, 15-28.	1.4	35
555	Expression of Voltage-Gated Calcium Channels in Tumor Cell Lines of Neuroectodermal or Other Origin. Annals of the New York Academy of Sciences, 1988, 540, 389-391.	4.5	2
556	Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line. Journal of Neuroimmunology, 1988, 19, 141-148.	2.4	46
557	Immunological and pharmacological heterogeneity of Î±-bungarotoxin binding sites extracted from TE671 cells. Journal of Neuroimmunology, 1988, 19, 149-157.	2.4	25
558	Epitopes on Human Acetylcholine Receptor Defined by Monoclonal Antibodies and Myasthenia Gravis Sera. Autoimmunity, 1988, 1, 285-297.	3.1	40

#	Article	IF	Citations
559	Monoclonal Anti-Acetycholine Receptor Antibodies as Probes for Human Acetylcholine-Receptor in Myasthenia Gravis. Journal of Receptors and Signal Transduction, 1988, 8, 143-159.	1.0	1
560	Neuroimmunology of myasthenia gravis. Brain, Behavior, and Immunity, 1988, 2, 346-351.	4.3	6
561	Differences in Fine Specificity of Anti-Acetylcholine Receptor Antibodies between Subgroups of Spontaneous Myasthenia Gravis of Recent Onset, and of Penicillamine Induced Myasthenia. Autoimmunity, 1988, 2, 31-37.	3.1	12
562	Antiâ€acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology, 1988, 38, 1784-1784.	1.3	32
563	Disorders Affecting the Acetylcholine Receptor: Myasthenia Gravis and Congenital Myasthenia. Journal of Receptors and Signal Transduction, 1987, 7, 599-616.	1.0	6
564	Expression of voltage-gated calcium channels in tumour cell lines of neuroectodermal or other origin. Journal of Neuroimmunology, 1987, 16, 101-102.	2.4	0
565	Epitopes on human ACHR defined by monoclonal antibodies. Journal of Neuroimmunology, 1987, 16, 178-179.	2.4	0
566	Immunological Heterogeneity and Cellular Mechanisms in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1987, 505, 12-26.	4.5	52
567	Antibody Heterogeneity and Specificity in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1987, 505, 106-120.	4.5	68
568	Lambert-Eaton Myasthenic Syndrome IgG: Early Morphologic Effects and Immunolocalization at the Motor Endplate. Annals of the New York Academy of Sciences, 1987, 505, 333-345.	4.5	15
569	Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study. Annals of Neurology, 1987, 22, 212-222.	6.6	211
570	MYASTHENIA GRAVIS WITHOUT ACETYLCHOLINE-RECEPTOR ANTIBODY: A DISTINCT DISEASE ENTITY. Lancet, The, 1986, 327, 116-119.	35.3	195
571	Monoclonal antibodies that distinguish between normal and denervated human acetylcholine re receptor. Journal of Neuroimmunology, 1986, 11, 223-235.	2.4	51
572	Myasthenia gravis. Neurology, 1986, 36, 612-612.	1.3	42
573	Monoclonal antibodies to Torpedo acetylcholine receptor. Characterisation of antigenic determinants within the cholinergic binding site. FEBS Journal, 1985, 150, 533-539.	0.3	36
574	Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.. Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 1246-1252.	2.0	413
575	4 Acetylcholine receptors and myasthenia gravis. Clinics in Endocrinology and Metabolism, 1983, 12, 57-78.	2.8	6
576	Acetycholine receptor antibody characteristics in myasthenia gravisâ˜†Fractionation of Î±-Bungarotoxin binding site antibodies and their relationship to IgG subclass. Journal of Neuroimmunology, 1983, 5, 1-9.	2.4	31

#	Article	IF	Citations
577	Immunological aspects of acetycholine receptors. Trends in Neurosciences, 1983, 6, 249-251.	13.4	4
578	Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis.. Journal of Neurology, Neurosurgery and Psychiatry, 1983, 46, 383-387.	2.0	27
579	Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 7636-7640.	7.7	280
580	Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology, 1983, 33, 1276-1276.	1.3	83
581	Anti-acetylcholine receptor antibody: Use of polyethylene glycol as an aid to precipitation of antibody-receptor complexes in determination of light chain and subclass. Journal of Immunological Methods, 1982, 51, 359-369.	1.5	9
582	Purification of anti-acetylcholine receptor antibody from patients with myasthenia gravis. Journal of Immunological Methods, 1982, 51, 371-381.	1.5	19
583	Acetylcholine Receptor Antibody: Clinical and Experimental Aspects. Novartis Foundation Symposium, 1982, , 225-247.	1.0	8
584	ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY SYNTHESIS BY CULTURED LYMPHOCYTES IN MY ASTHENIA GRAVIS: THYMIC AND PERIPHERAL BLOOD CELL INTERACTIONS. Annals of the New York Academy of Sciences, 1981, 377, 393-402.	4.5	30
585	ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY HETEROGENEITY IN DIFFERENT FORMS OF MYASTHENIA GRAVIS. Annals of the New York Academy of Sciences, 1981, 377, 895-897.	4.5	0
586	AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROME. Lancet, The, 1981, 318, 224-226.	35.3	321
587	Idiotype restriction in myasthenia gravis antibodies. Nature, 1981, 290, 293-294.	40.1	14
588	Acetylcholine receptor antibody synthesis by thymic lymphocytes. Neurology, 1981, 31, 935-935.	1.3	160
589	Anti-acetylcholine receptor antibodies.. Journal of Neurology, Neurosurgery and Psychiatry, 1980, 43, 590-600.	2.0	138
590	CLINICAL, PATHOLOGICAL, HLA ANTIGEN AND IMMUNOLOGICAL EVIDENCE FOR DISEASE HETEROGENEITY IN MYASTHENIA GRAVIS. Brain, 1980, 103, 579-601.	8.9	437
591	Tissue-specific antibodies in myasthenia gravis.. Journal of Clinical Pathology, 1979, s3-13, 97-106.	1.7	4
592	Acetylcholine in Intercostal Muscle from Myasthenia Gravis Patients and in Rat Diaphragm after Blockade of Acetylcholine Receptors. Progress in Brain Research, 1979, , 449-458.	0.0	38
593	IN-VITRO SYNTHESIS OF ANTI-ACETYLCHOLINE-RECEPTOR ANTIBODY BY THYMIC LYMPHOCYTES IN MYASTHENIA GRAVIS. Lancet, The, 1978, 311, 305-307.	35.3	130
594	ACETYLCHOLINE RECEPTORS AND END-PLATE ELECTROPHYSIOLOGY IN MYASTHENIA GRAVIS. Brain, 1978, 101, 345-368.	8.9	108

#	Article	IF	Citations
595	Function of circulating antibody to acetylcholine receptor in myasthenia gravis. Neurology, 1978, 28, 266-266.	1.3	246
596	Myasthenia gravis â€" latest developments. Trends in Biochemical Sciences, 1977, 2, N275-N276.	8.1	0
597	Acetylcholine in human muscle. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1976, 192, 475-480.	3.2	31
598	Experimental myasthenia gravis â€" a new autoimmune model. Trends in Biochemical Sciences, 1976, 1, 289-291.	8.1	0
599	New support for autoimmune basis of myasthenia gravis. Nature, 1975, 256, 10-11.	40.1	1
600	Neuromuscular transmission after immunization against acetylcholine receptors. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1975, 189, 57-68.	3.2	58
601	Acetylcholine receptors. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences, 1975, 270, 551-559.	2.4	40
602	Autoimmune Myasthenias. , 0, , 78-85.		0